- Home
- RLYB vs CGTX Comparison
RLYB vs CGTX Comparison
Compare RLYB & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- CGTX
- Stock Information
- Founded
- RLYB 2018
- CGTX 2007
- Country
- RLYB United States
- CGTX United States
- Employees
- RLYB N/A
- CGTX N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- CGTX Health Care
- Exchange
- RLYB Nasdaq
- CGTX Nasdaq
- Market Cap
- RLYB 27.2M
- CGTX 26.8M
- IPO Year
- RLYB 2021
- CGTX 2021
- Fundamental
- Price
- RLYB $0.64
- CGTX $0.42
- Analyst Decision
- RLYB Buy
- CGTX Strong Buy
- Analyst Count
- RLYB 5
- CGTX 6
- Target Price
- RLYB $9.75
- CGTX $7.50
- AVG Volume (30 Days)
- RLYB 45.7K
- CGTX 661.9K
- Earning Date
- RLYB 03-13-2025
- CGTX 03-20-2025
- Dividend Yield
- RLYB N/A
- CGTX N/A
- EPS Growth
- RLYB N/A
- CGTX N/A
- EPS
- RLYB N/A
- CGTX N/A
- Revenue
- RLYB $636,000.00
- CGTX N/A
- Revenue This Year
- RLYB N/A
- CGTX N/A
- Revenue Next Year
- RLYB N/A
- CGTX N/A
- P/E Ratio
- RLYB N/A
- CGTX N/A
- Revenue Growth
- RLYB N/A
- CGTX N/A
- 52 Week Low
- RLYB $0.61
- CGTX $0.34
- 52 Week High
- RLYB $3.46
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- RLYB 43.29
- CGTX 38.31
- Support Level
- RLYB $0.62
- CGTX $0.41
- Resistance Level
- RLYB $0.73
- CGTX $0.50
- Average True Range (ATR)
- RLYB 0.08
- CGTX 0.04
- MACD
- RLYB 0.00
- CGTX 0.01
- Stochastic Oscillator
- RLYB 19.27
- CGTX 26.05
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.